Juergens R - Search Results

1

Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.

Colomer-Lahiguera S, Bryant-Lukosius D, Rietkoetter S, Martelli L, Ribi K, Fitzpatrick-Lewis D, Sherifali D, Orcurto A, Juergens R, Eicher M. Colomer-Lahiguera S, et al. Among authors: juergens r. J Patient Rep Outcomes. 2020 Jul 16;4(1):58. doi: 10.1186/s41687-020-00210-z. J Patient Rep Outcomes. 2020. PMID: 32676785 Free PMC article.

2

Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Price PW, Jao K, Schellenberg DD, Juergens R, Leighl N, Chu Q. Melosky B, et al. Among authors: juergens r. Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub 2020 Sep 23. Oncologist. 2020. PMID: 32860288 Free PMC article. Review.

3

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.

Iafolla MAJ, Juergens RA. Iafolla MAJ, et al. Front Oncol. 2017 Apr 6;7:67. doi: 10.3389/fonc.2017.00067. eCollection 2017. Front Oncol. 2017. PMID: 28428947 Free PMC article. Review.

4

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q. Melosky B, et al. Among authors: juergens r. Oncologist. 2020 Jan;25(1):64-77. doi: 10.1634/theoncologist.2019-0027. Epub 2019 May 28. Oncologist. 2020. PMID: 31138727 Free PMC article. Clinical Trial.

5

Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Melosky B, et al. Among authors: juergens r. Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.

6

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.

Chan SWS, Shukla R, Ramsay J, McWhirter E, Barnfield P, Juergens RA. Chan SWS, et al. Among authors: juergens ra. Curr Oncol. 2023 Apr 27;30(5):4527-4537. doi: 10.3390/curroncol30050342. Curr Oncol. 2023. PMID: 37232800 Free PMC article.

7

Imaging Biomarkers in Immunotherapy.

Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. Juergens RA, et al. Biomark Cancer. 2016 Feb 25;8(Suppl 2):1-13. doi: 10.4137/BIC.S31805. eCollection 2016. Biomark Cancer. 2016. PMID: 26949344 Free PMC article. Review.

8

Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer.

Seow H, Tanuseputro P, Barbera L, Earle C, Guthrie D, Isenberg S, Juergens R, Myers J, Brouwers M, Sutradhar R. Seow H, et al. Among authors: juergens r. JAMA Netw Open. 2020 Apr 1;3(4):e201768. doi: 10.1001/jamanetworkopen.2020.1768. JAMA Netw Open. 2020. PMID: 32236529 Free PMC article.

9

Immuno-oncology-the new paradigm of lung cancer treatment.

Dawe DE, Harlos CH, Juergens RA. Dawe DE, et al. Among authors: juergens ra. Curr Oncol. 2020 Apr;27(Suppl 2):S78-S86. doi: 10.3747/co.27.5183. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368177 Free PMC article. Review.

10

Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis.

Lee Y, Samarasinghe Y, Lee MH, Thiru L, Shargall Y, Finley C, Hanna W, Levine O, Juergens R, Agzarian J. Lee Y, et al. Among authors: juergens r. Ann Surg. 2022 Jan 1;275(1):91-98. doi: 10.1097/SLA.0000000000005227. Ann Surg. 2022. PMID: 34596073

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page